CN113825760A - 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 - Google Patents

一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 Download PDF

Info

Publication number
CN113825760A
CN113825760A CN202080034445.5A CN202080034445A CN113825760A CN 113825760 A CN113825760 A CN 113825760A CN 202080034445 A CN202080034445 A CN 202080034445A CN 113825760 A CN113825760 A CN 113825760A
Authority
CN
China
Prior art keywords
degrees
compound
formula
ray powder
angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080034445.5A
Other languages
English (en)
Other versions
CN113825760B (zh
Inventor
陈新海
陈兆国
张丽
于衍新
周凯
姜奋
夏尚华
王校飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN113825760A publication Critical patent/CN113825760A/zh
Application granted granted Critical
Publication of CN113825760B publication Critical patent/CN113825760B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明公开了一种mTORC1/2双激酶抑制剂的盐型、晶型及其制备方法，还包括所述盐型和晶型在制备mTORC1/2双激酶抑制剂相关药物中的应用。(I)

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN202080034445.5A 2019-05-06 2020-05-06 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 Active CN113825760B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019103730719 2019-05-06
CN201910373071 2019-05-06
CN201910380491 2019-05-08
CN201910380491X 2019-05-08
PCT/CN2020/088748 WO2020224585A1 (zh) 2019-05-06 2020-05-06 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN113825760A true CN113825760A (zh) 2021-12-21
CN113825760B CN113825760B (zh) 2022-08-19

Family

ID=73051250

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080034445.5A Active CN113825760B (zh) 2019-05-06 2020-05-06 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法

Country Status (5)

Country Link
US (1) US20220306622A1 (zh)
EP (1) EP3967698A4 (zh)
JP (1) JP7307817B2 (zh)
CN (1) CN113825760B (zh)
WO (1) WO2020224585A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101558067A (zh) * 2006-08-23 2009-10-14 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
CN103030653A (zh) * 2011-09-30 2013-04-10 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用
CN103588792A (zh) * 2013-03-04 2014-02-19 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2648388T3 (es) 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR
CN111315750B (zh) * 2017-11-06 2022-12-23 南京明德新药研发有限公司 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101558067A (zh) * 2006-08-23 2009-10-14 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
CN103030653A (zh) * 2011-09-30 2013-04-10 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用
CN103588792A (zh) * 2013-03-04 2014-02-19 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PIKE KURT G. 等: "Optimization of Potent and Selective Dual mTORC1 and mTORC2 Inhibitors: The Discovery of AZD8055 and AZD2014", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
JP7307817B2 (ja) 2023-07-12
WO2020224585A1 (zh) 2020-11-12
CN113825760B (zh) 2022-08-19
EP3967698A4 (en) 2022-10-19
EP3967698A1 (en) 2022-03-16
US20220306622A1 (en) 2022-09-29
JP2022532099A (ja) 2022-07-13

Similar Documents

Publication Publication Date Title
CN111285851A (zh) 靶向降解黏着斑激酶的化合物及其在医药上的应用
US11680061B2 (en) Crystal forms C and E of pyrazin-2(1H)-one compound and preparation method therefor
CN112912380A (zh) 一种mek抑制剂的晶型、无定形及其应用
CN114728957B (zh) 一种atr抑制剂的晶型及其应用
CN113825760B (zh) 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
CN114315837B (zh) 一种erk抑制剂的结晶形式及其制备方法
CN115448874A (zh) 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
EP3896063B1 (en) Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1)
CN114144418B (zh) 喹唑啉类化合物的晶型、盐型及其制备方法
CN111886228B (zh) 一种c-MET/AXL抑制剂的晶型
CN113646312B (zh) 固体形式的brd4抑制剂化合物及其制备方法与应用
CN110437149B (zh) 抗肿瘤活性的天然萘基异喹啉类化合物及其组合物、应用
TW202221001A (zh) 吡咯並雜環類衍生物的晶型及其製備方法
US20220213060A1 (en) Crystal Form of Quinazolinone Compound and Preparation Method Therefor
WO2014111031A1 (zh) 三嗪化合物、其药用盐、异构体或水合物及其药物组合物
CN115052877B (zh) 一种氮杂吲哚衍生物的晶型及其应用
CN113874364B (zh) 一种嘧啶磺酰胺类化合物的晶型及其制备方法
CN113646313B (zh) 一种a2a受体拮抗剂的盐型、晶型及其制备方法
WO2022048545A1 (zh) 一种吡啶并嘧啶化合物的晶型
CN113784968B (zh) Wee1抑制剂化合物的晶型及其应用
CN117355528A (zh) 吡咯并三嗪类化合物的盐型、其晶型及其制备方法
CN115650975A (zh) 一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用
CN114945565A (zh) 一种吡咯烷基脲衍生物的晶型及其应用
CN115232124A (zh) 一种atx抑制剂的结晶形式及其制备方法
CN116867491A (zh) 3,4-二氢异喹啉类化合物的盐及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062028

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant